Valuation dashboard for None (QURE) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other peers companies.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.
Analysis Summary
None reported revenue of $16.1M in the most recent fiscal year, growing at a 5-year CAGR of -15.6%.
Balance sheet quality for QURE: current ratio of 10.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $-8.17 |
| vs Current Price | -119.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| QURE | |||||
| EWTX | Edgewise Therapeutics, Inc. | $4.9B | 10.73 | ||
| GPCR | Structure Therapeutics Inc. | $2.0B | 1.92 | -16.9% | |
| CLDX | Celldex Therapeutics, Inc. | $2.6B | 4.25 | -52.4% | |
| OCUL | Ocular Therapeutix, Inc. | $2.3B | 4.41 | -59.9% | |
| ABCL | AbCellera Biologics Inc. | $3.5B | 3.98 | -17.5% | |
| NUVB | Nuvation Bio Inc. | $2.0B | 7.68 | -66.9% |
Price
| Price | $42.49 |
| Market Cap | $2.9B |
Related companies: ABCL · CLDX · EWTX · GLPG · GPCR · MESO · NUVB
More sections of QURE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks